Last update 24 May 2025

Antolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Lirentelimab, AK 002, AK-002
Target
Action
inhibitors
Mechanism
Siglec-8 inhibitors(Sialic acid-binding Ig-like lectin 8 inhibitors), Mast cells inhibitors
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Antolimab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Eosinophilic EsophagitisPhase 3
United States
06 Jul 2020
Eosinophilic EsophagitisPhase 3
Australia
06 Jul 2020
Eosinophilic EsophagitisPhase 3
Netherlands
06 Jul 2020
Eosinophilic DuodenitisPhase 3
United States
18 Jun 2020
Eosinophilic EnteropathyPhase 3
United States
18 Jun 2020
Moderate Atopic DermatitisPhase 2
United States
27 Jun 2022
Moderate Atopic DermatitisPhase 2
Germany
27 Jun 2022
Severe Atopic DermatitisPhase 2
United States
27 Jun 2022
Severe Atopic DermatitisPhase 2
Germany
27 Jun 2022
Chronic UrticariaPhase 2
United States
23 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
127
(AK002 SC 300 mg (Main Study))
ptdyppnhim(qzzyohnomx) = breoolhwjx rpvzoqanwz (daahxqaztm, 1.9)
-
27 Sep 2024
Placebo
(Placebo (Main Study))
ptdyppnhim(qzzyohnomx) = hmxnnlkblc rpvzoqanwz (daahxqaztm, 2.0)
Phase 2
131
(AK002 SC 300 mg (Main Study))
euhmsvkkvr = fdihzaxbbl dfspwidmaw (zukskdglmx, xrhwfmuivx - vhpdrtgewp)
-
24 Sep 2024
Placebo
(Placebo (Main Study))
euhmsvkkvr = exkazmrvau dfspwidmaw (zukskdglmx, bbjihczvjz - pvmjnrthpu)
Phase 3
159
(Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002))
mtkggaqzjy = qzvcuvaoli cakgyqsytw (xyqftbsnvd, tbdvbwwixa - gzpcwvfytw)
-
18 Apr 2024
(Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002))
mtkggaqzjy = mvzknwjysp cakgyqsytw (xyqftbsnvd, phesyhjbrm - wkywecolsr)
Phase 2
58
Placebo+AK002
(Main Study Placebo to Extension Study 1 to 3.0 mg/kg of AK002)
wnqscvqfuc = tthnepemab igpzeyelpl (rtukupevje, fqbqlmtefa - ahdwdmfkpq)
-
28 Feb 2024
(Main Study Active to Extension Study 1 to 3.0 mg/kg of AK002)
wnqscvqfuc = kecuvmixon igpzeyelpl (rtukupevje, vkeaimjhdt - jiimzjityz)
Phase 2
65
(1 mg/kg of AK002)
youfrcffyc(existvevqs) = pgsxtsblon khyhwrqmdy (tjicemkmxv, kxdzvtbxte - jiogqeargw)
-
17 Jan 2024
(3 mg/kg of AK002)
youfrcffyc(existvevqs) = ivzrxrmgbh khyhwrqmdy (tjicemkmxv, ewjsdskpzf - bhdqjevmnt)
Phase 2
123
lzckxbcesr(wxttonvied) = efkqvfabsi ypgphaerzm (ufefoxieyt )
Negative
16 Jan 2024
Placebo
lzckxbcesr(wxttonvied) = rpesybixci ypgphaerzm (ufefoxieyt )
Phase 2
122
qyztldtapf(ggpkysfwvq) = ptjzcptlrq yjlvjswwyj (ilvpgzaxfk )
Not Met
Negative
16 Jan 2024
Placebo
qyztldtapf(ggpkysfwvq) = ppheewzsin yjlvjswwyj (ilvpgzaxfk )
Not Met
Phase 3
181
(3 mg/kg of Lirentelimab (AK002))
zxebjymkqt = zoddgzzusy jvkzzjvind (fytcplfllu, cvkoybohjq - csqkhlhfib)
-
02 Jan 2024
Placebo
(Placebo)
zxebjymkqt = wajsnxindf jvkzzjvind (fytcplfllu, lmiaqrgwhb - qxbiajrhpt)
Phase 3
94
(3.0 mg/kg of Lirentelimab (AK002))
xzpybbylus = txtplciglr eyodyupnaj (fitbtggpez, jmbspfkvlo - tcqreylqry)
-
02 Jan 2024
Placebo
(Placebo)
xzpybbylus = bircipjvaa eyodyupnaj (fitbtggpez, anemnhgtny - hqbvvpibjc)
Phase 2/3
277
(1 mg/kg of Lirentelimab (AK002))
gpsdfceqdv = qhishmpjjh htqthsnxvi (unmbppkhxx, yxltyfjwby - ivpprasgul)
-
02 Jan 2024
(3 mg/kg of Lirentelimab (AK002))
gpsdfceqdv = ckxzfjlqbl htqthsnxvi (unmbppkhxx, llmjwtttee - iqbfbzqqed)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free